Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B

Cell Cycle

Volumn 11, Issue 9, 2012, Pages 1773-1781

  Cai, Chunlin ^a   Rajaram, Megha ^a,b   Zhou, Xin ^a,b   Liu, Qing ^a   Marchica, John ^a   Li, Jinyu ^a   Powers, R Scott ^a,b  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Amplification; EMT; Golgi; Oncogene; Tumor maintenance

Indexed keywords

ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

AMPLICON; ANIMAL CELL; ARTICLE; CANCER CELL; CELL SURFACE; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CHROMOSOME 3Q; CONTROLLED STUDY; COPY NUMBER VARIATION; EPITHELIAL MESENCHYMAL TRANSITION; FNDC3B GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE PRODUCT; GENE SILENCING; GOLGI COMPLEX; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; ONCOGENE; OVARY CANCER;

EID: 84860728629     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20121     Document Type: Article

References (41)

1. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331:1553-8; PMID:21436442; http://dx.doi.org/10.1126/science. 1204040.
2. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470:187-97; PMID:21307931; http://dx.doi.org/10.1038/nature09792.
3. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011; 19:347- 58; PMID:21397858; http://dx.doi.org/10.1016/j. ccr.2011.01.040.
4. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135:852-64; PMID:19012953; http://dx.doi. org/10.1016/j.cell.2008.09.061.
5. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 2011; 20:92-103; PMID:21741599; http://dx.doi. org/10.1016/j.ccr.2011.05. 025.
6. Tominaga K, Kondo C, Johmura Y, Nishizuka M, Imagawa M. The novel gene fad104, containing a fibronectin type III domain, has a significant role in adipogenesis. FEBS Lett 2004; 577:49-54; PMID:15527760; http://dx.doi.org/10. 1016/j.febslet. 2004.09.062.
7. Nishizuka M, Kishimoto K, Kato A, Ikawa M, Okabe M, Sato R, et al. Disruption of the novel gene fad104 causes rapid postnatal death and attenuation of cell proliferation, adhesion, spreading and migration. Exp Cell Res 2009; 315:809-19; PMID:19138685; http:// dx.doi.org/10.1016/j.yexcr.2008.12.013.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013.
9. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 2007; 104:16663-8; PMID:17925434; http://dx.doi. org/10.1073/pnas.0708286104.
10. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102; PMID:9916799; http://dx.doi.org/10.1038/5042.
11. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, et al. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2008; 2:164- 81; PMID:19383336; http://dx.doi.org/10.1016/j. molonc.2008.05.001.
12. Linxweiler M, Linxweiler J, Barth M, Benedix J, Jung V, Kim YJ, et al. Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol 2012; 180:473- 83; PMID:22197383; http://dx.doi.org/10.1016/j. ajpath.2011.10.039.
13. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage- survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41:1238-42; PMID:19801978; http://dx.doi.org/10. 1038/ng.465.
14. Pollack JR, Sørlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002; 99:12963-8; PMID:12297621; http://dx.doi.org/10.1073/pnas. 162471999.
15. Kim RH, Wang D, Tsang M, Martin J, Huff C, de Caestecker MP, et al. A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGFbeta signal transduction. Genes Dev 2000; 14:1605-16; PMID:10887155.
16. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, et al. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000; 14:1319- 31; PMID:10837025.
17. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420- 8; PMID:19487818; http://dx.doi.org/10.1172/ JCI39104.
18. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156:299-313; PMID:11790801; http://dx.doi. org/10.1083/jcb.200109037.
19. Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G. Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 2011; 11:417; PMID:21955753; http://dx.doi. org/10.1186/1471-2407-11-417.
20. Wattenberg B, Lithgow T. Targeting of C-terminal (tail)-anchored proteins: understanding how cytoplasmic activities are anchored to intracellular membranes. Traffic 2001; 2:66-71; PMID:11208169; http://dx.doi. org/10.1034/j.1600-0854.2001.20108.x.
21. Gao YS, Alvarez C, Nelson DS, Sztul E. Molecular cloning, characterization and dynamics of rat formiminotransferase cyclodeaminase, a Golgi-associated 58-kDa protein. J Biol Chem 1998; 273:33825- 34; PMID:9837973; http://dx.doi.org/10.1074/ jbc.273.50.33825.
22. Chen YG. Endocytic regulation of TGFbeta signaling. Cell Res 2009; 19:58-70; PMID:19050695; http:// dx.doi.org/10.1038/cr.2008.315.
23. Mendelsohn R, Cheung P, Berger L, Partridge E, Lau K, Datti A, et al. Complex N-glycan and metabolic control in tumor cells. Cancer Res 2007; 67:9771-80; PMID:17942907; http://dx.doi.org/10.1158/0008-5472.CAN-06-4580.
24. Sotillo R, Hernando E, Díaz-Rodríguez E, Teruya- Feldstein J, Cordón-Cardo C, Lowe SW, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007; 11:9-23; PMID:17189715; http://dx.doi.org/10.1016/j.ccr.2006.10.019.
25. Huesken D, Lange J, Mickanin C, Weiler J, Asselbergs F, Warner J, et al. Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 2005; 23:995-1001; PMID:16025102; http://dx.doi.org/10.1038/nbt1118.
26. Barrett JC, Crawford BD, Mixter LO, Schechtman LM, Ts'o PO, Pollack R. Correlation of in vitro growth properties and tumorigenicity of Syrian hamster cell lines. Cancer Res 1979; 39:1504-10; PMID:427793.
27. Yang X, Boehm JS, Yang X, Salehi-Ashtiani K, Hao T, Shen Y, et al. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 2011; 8:659-61; PMID:21706014; http://dx.doi. org/10.1038/nmeth.1638.
28. Kumar A, Agarwal S, Heyman JA, Matson S, Heidtman M, Piccirillo S, et al. Subcellular localization of the yeast proteome. Genes Dev 2002; 16:707- 19; PMID:11914276; http://dx.doi.org/10.1101/ gad.970902.
29. Pelech S. Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Curr Pharm Biotechnol 2004; 5:69-77; PMID:14965210; http://dx.doi.org/10.2174/1389201043489666.
30. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99; PMID:15286780; http://dx.doi.org/10.1038/nm1087.
31. Manning AL, Dyson NJ. pRB, a tumor suppressor with a stabilizing presence. Trends Cell Biol 2011; 21:433- 41; PMID:21664133; http://dx.doi.org/ 10.1016/j. tcb.2011.05.003.
32. Shi Y, Massagué J. Mechanisms of TGFbeta signaling from cell membrane to the nucleus. Cell 2003; 113:685-700; PMID:12809600; http://dx.doi. org/10.1016/S0092-8674(03)00432-X.
33. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-300; PMID:9331090.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545-50; PMID:16199517; http:// dx.doi.org/10.1073/pnas.0506580102.
35. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-7; PMID:16273092; http://dx.doi. org/10.1038/nature04296.
36. Györffy B, Schäfer R. Biomarkers downstream of RAS: a search for robust transcriptional targets. Curr Cancer Drug Targets 2010; 10:858-68; PMID:20718707; http://dx.doi.org/10.2174/156800910793357916.
37. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29:2013-23; PMID:20101236; http://dx.doi. org/10.1038/onc.2009.489.
38. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 2006; 45:761-9; PMID:16708353; http://dx.doi.org/10.1002/ gcc.20339.
39. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007; 67:2081-8; PMID:17332337; http://dx.doi.org/10.1158/0008-5472.CAN-06-3495.
40. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70:2085-94; PMID:20179196; http://dx.doi.org/10.1158/0008-5472.CAN-09-3746.
41. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 2007; 13:5745-55; PMID:17908964; http://dx.doi.org/10. 1158/1078-0432.CCR-06-2882.